Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Ochronosis

Ochronosis, often called alkaptonuric ochronosis, is an autosomal recessive metabolic disorder that causes an excess of homogentisic acid, resulting in adverse pigmentation, calcification, and inflammation of cartilagenous and related tissue throughout the body. The disorder is a result of incomplete metbolism of homogentisic acid, tyrosine and phenylalanine. The face, skeletal system, cardiovascular system, respiratory system, urinary system and to a lesser degree, the skin, are affected by this disease. (From the Wikpedia article Ochronosis.)

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Recent Publications on Ochronosis:

Pubmed Logo
Joint and tendineous involvement in ochronosis: clinical history and imaging of a case.
We describe a case of a previously healthy 35-year-old man who presents...
13th November, 2009
Clin Exp Rheumatol. 2009 Jul-Aug;27(4):696-7.
Melasma in Latin America: options for therapy and treatment algorithm.
OBJECTIVE/AIM: To examine approaches to therapy for melasma in Latin...
3rd November, 2009
University of Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, J Eur Acad Dermatol Venereol. 2009 Jul;23(7):760-72.
DOI Direct Link
Skin bleaching: highlighting the misuse of cutaneous depigmenting agents.
Hydroquinone and other cutaneous depigmenting agents are widely used by...
3rd November, 2009
Department of Dermatology, Chelsea and Westminster Hospital, London, UK. J Eur Acad Dermatol Venereol. 2009 Jul;23(7):741-50. Epub 2009 Mar 11.
DOI Direct Link
Mutation spectrum of homogentisic acid oxidase (HGD) in alkaptonuria.
Alkaptonuria (AKU) is a rare autosomal recessive metabolic disorder,...
29th October, 2009
Medical Genetics Branch, National Human Genome Research Institute, Hum Mutat. 2009 Sep 4.
DOI Direct Link
Comparative study on low back pain misdiagnosed as spondyloarthropathy.
This study aims to investigate features of different diseases with low...
14th October, 2009
Department of Rheumatology and Immunology, Peking University Third Clin Rheumatol. 2009 Aug;28(8):893-8. Epub 2009 May 17.
DOI Direct Link

View more research publications.

Ochronosis Patents:

USPTO Logo
US Patent No.Title
7528153 Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
6231343 Method for bleaching discolored tooth by titanium dioxide photocatalyst
6118050 Hydroxyphenylpyruvate dioxygenase gene from arabidopsis and method of screening for inhibitors thereof
6017960 Method of treating post-inflammatory hyperpigmentation in black skin with a retinoid, and method of lightening black skin with a retinoid
5750570 Method of treatment of hyperpigmentation in black skin with retinoic acid and method of lightening black skin with retinoic acid

View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Ochronosis scientists - we have details of around 61 individuals working on Ochronosis .


This page has been viewed 365 times
Recent Search Terms used to find this page: causes of Ochronosis | skin ochronosis | ochronosis | skin ochronosis | ocranosis | ochronosis | what causes skin ochronosis | ochronosis | alkaptonuria knee surgeon | .
Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Ochronosis across BioPortfolio, or for Ochronosis Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.